参芪泻白散联合化疗对晚期非小细胞肺癌患者生活质量及免疫功能的影响  

Impacts on Life Quality and Immune Function in the Patients of Non-Small Cell Lung Cancer at the Late Stage Treated with Shenqi Xiebai Powder Combined with Chemotherapy

作　　者：卢旭全 袁颖[1] 黄智芬[1] 黎汉忠[1] 谭志强[1] 张丽娜[1] 桂海涛[1] 许瑞琪[1] 

机构地区：[1]广西中医药大学,广西南宁530001

出　　处：《世界中西医结合杂志》2014年第4期382-385,共4页World Journal of Integrated Traditional and Western Medicine

基　　金：广西壮族自治区卫生厅自筹经费科研课题(No.Z2009243)

摘　　要：目的观察参芪泻白散联合化疗对晚期非小细胞肺癌(NSCLC)患者生活质量及免疫功能的影响。方法将72例患者按随机数字表单盲法分为治疗组(37例)和对照组(35例)。对照组采用TP方案化疗,治疗组在对照组的基础上于化疗前2 d加用参芪泻白散治疗。28 d为1个周期,连续2个周期。观察两组患者治疗前后中医证候积分、生活质量积分、KPS评分、免疫功能及不良反应变化。结果治疗组经治疗后中医证候积分、生活质量积分和KPS评分均有改善,与本组治疗前和对照组治疗后比较,差异均有统计学意义(P<0.05)。对照组治疗后中医证候积分升高,生活质量积分、KPS评分降低,与本组治疗前比较,差异均有统计学意义(P<0.05)。两个周期化疗后,对照组CD4+、CD4+/CD8+水平较治疗前明显下降(P<0.05),而治疗组CD3+、CD4+、CD8+、CD4+/CD8+水平较治疗前有所增加(P<0.05)。两组间比较,治疗后治疗组CD4+、CD4+/CD8+水平较对照组高(P<0.05)。两组不良反应发生率治疗组低于对照组(P<0.05)。结论参芪泻白散联合化疗治疗晚期NSCLC可提高机体免疫功能,改善临床症状,减少不良反应,提高生活质量,延长生存期。Objective To observe the impacts on life quality and immune function of the patients of non- small cell lung cancer at the late stage （NSCLC）treated with Shenqi Xiebai Powder combined with chemotherapy. Methods Seventy - two patients were divided into a treatment group （37 cases） and a control group（ 35 cases）according to random number table. In the control group, TP program of chemotherapy was a- dopted. In the treatment group, on the basic treatment as the control group ,2 days before chemotherapy, Shen- qi Xiebai Powder was supplemented. The treatment of 28 days was 1 period and 2 periods were required con- tinuously. The symptom score of Chinese medicine, the score of life quality, KPS score, immune function and adverse reactions were observed before and after treatment in the patients of two groups. Results The symp- tom score of Chinese medicine, the score of life quality and KPS score were all improved after treatment in the treatment group, indicating the significant differences as compared with those before treatment in the same group and those after treatment in the control （ P 〈 0.05 ）. After two periods of chemotherapy, CD4 ＋ and CD4 ＋/CD8 ＋ levels were reduced apparently as compared with those before treatment in the control group（ P 〈 0.05 ） ;the levels of CD3 ＋ , CD4 ＋ , CD8＋ and CD4 ＋/CD8 ＋ were all increased as compared with those be- fore treatment in the treatment group （ P 〈 0.05 ）. In comparison of the two groups, the levels of CD4 ＋ and CD4 ＋/CD8 ＋ in the treatment group were higher than those in the control group after treatment（ P 〈 0.05 ）. The incidence of the adverse reactions in the treatment group was lower than that in the control group（ P 〈 0.05）. Conclusion The combined therapy of Shenqi Xiebai Powder and chemotherapy improves body im- mune function, relieves clinical symptoms, reduces adverse reactions, enhances life quality and prolongs life span in the patients of NSCLC at the late stage.

关 键 词：非小细胞肺癌 参芪泻白散 化疗疗法 生活质量 免疫功能 

分 类 号：R734.1[医药卫生—肿瘤]